Acrivon Therapeutics (ACRV) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 13, 2025, to be held virtually, with voting and Q&A available online.

• Stockholders will vote on electing three Class III directors for three-year terms and ratifying the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2025.

• The board encourages prompt voting and offers multiple methods for participation, including online, phone, and mail.

Voting matters and shareholder proposals

• Proposal 1: Elect Peter Blume-Jensen, Derek DiRocco, and Santhosh Palani as Class III directors for terms expiring in 2028.

• Proposal 2: Ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2025.

• No other proposals are anticipated, but proxies confer discretionary authority to vote on any new matters.

• Stockholders may submit proposals for the 2026 meeting by December 26, 2025, and must follow specific procedures for nominations and proposals.

Board of directors and corporate governance

• The board consists of eight directors divided into three classes with staggered three-year terms.

• Six of eight directors are independent; the CEO and EVP are not independent and are married.

• Board committees include audit, compensation, and nominating/governance, each with defined charters and independent membership.

• All directors attended at least 75% of meetings in 2024; a code of conduct and insider trading policy are in place.